| B24 | Dolutegravir-based regimen is associated with metabolic syndrome components among persons with HIV in sub-Saharan Africa | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| B24 | Weight gain following the single substitution of TDF by TAF in people living with HIV (PLWH) in the French Dat'AIDS cohort | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| B24 | Weight changes, metabolic syndrome and all-cause mortality in persons living with HIV | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| B24 | Patterns of weight gain in Bictegravir/Emtricitabine/Tenofovir alafenamide (B) | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| B24 | Does weight gain on Bictegravir/Emtricitabine/Tenofovir Alafenamide (B) lead to metabolic syndrome? | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| B24 | Weight gain or 'return to health'? Changes in body weight in aging people living with HIV compared with the general population from the German Ruhr-area over 5 years | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| B24 | Low proportion of individuals develop Metabolic Syndrome (MetS) or hepatic fibrosis after switch to Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in virologically suppressed patients: a post-hoc metabolic analysis | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| B24 | Obesity, raised blood pressure and diabetes in women with and without HIV: a pooled analysis of 17,450 women in four countries in sub-Saharan Africa | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| B24 | Metabolic syndrome and estimated 10-year cardiovascular disease risk among HIV-positive and HIV-negative adults in Zambia and Zimbabwe | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |
| B24 | Endocrine pathways of non-alcoholic fatty liver disease (NAFLD) in people living with HIV | E-poster | Metabolic, lipid and endocrine complications (including obesity, hyperlipidaemia and lipodystrophy) |